Free tool
FAERS Monitor: Sylvant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125496 or its brand name (Sylvant, Siltuximab). Reports on generic versions are filed under their own applications.
Reports
649
Serious
536
83% of reports
Hospitalization
209
Death reported
137
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use140
- drug ineffective98
- cytokine release syndrome60
- immune effector cell-associated neurotoxicity syndrome47
- hypertension44
- disease progression40
- death37
- drug effective for unapproved indication33
- cataract32
- hepatic steatosis31
- cushingoid30
- osteopenia30
- short stature30
- product use in unapproved indication27
- spinal instability25
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 6 |
| 2014 | 8 |
| 2015 | 23 |
| 2016 | 14 |
| 2017 | 9 |
| 2018 | 22 |
| 2019 | 35 |
| 2020 | 80 |
| 2021 | 68 |
| 2022 | 53 |
| 2023 | 61 |
| 2024 | 106 |
| 2025 | 87 |
| 2026 | 77 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,510 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| short statureSignal | 30 | 4194.8 | 2890.5 | 107,700 |
| spinal instabilitySignal | 25 | 3541.5 | 2360.6 | 76,618 |
| cushingoidSignal | 30 | 305.7 | 215.2 | 8,729 |
| immune effector cell-associated neurotoxicity syndromeSignal | 47 | 259.2 | 196.6 | 11,742 |
| cytokine release syndromeSignal | 60 | 97.2 | 76.4 | 5,607 |
| osteopeniaSignal | 30 | 64.2 | 45.2 | 1,801 |
| hepatic steatosisSignal | 31 | 54.0 | 38.3 | 1,560 |
| drug effective for unapproved indicationSignal | 33 | 36.6 | 26.2 | 1,106 |
| cataractSignal | 32 | 17.4 | 12.4 | 480 |
| disease progressionSignal | 40 | 11.0 | 8.1 | 354 |
| hypertensionSignal | 44 | 6.7 | 5.1 | 211 |
| off label useSignal | 140 | 5.2 | 4.5 | 489 |
| product use in unapproved indicationSignal | 27 | 3.5 | 2.4 | 47 |
| drug ineffectiveSignal | 98 | 2.4 | 2.0 | 85 |
| death | 37 | 1.4 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.